Bio Total Current Liabilities vs Short Term Debt Analysis
BIO Stock | USD 287.21 0.00 0.00% |
Bio Rad financial indicator trend analysis is way more than just evaluating Bio Rad Laboratories prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Rad Laboratories is a good investment. Please check the relationship between Bio Rad Total Current Liabilities and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
Total Current Liabilities vs Short Term Debt
Total Current Liabilities vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Rad Laboratories Total Current Liabilities account and Short Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Bio Rad's Total Current Liabilities and Short Term Debt is 0.59. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Bio Rad Laboratories, assuming nothing else is changed. The correlation between historical values of Bio Rad's Total Current Liabilities and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Bio Rad Laboratories are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Total Current Liabilities i.e., Bio Rad's Total Current Liabilities and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.59 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Current Liabilities
Total Current Liabilities is an item on Bio Rad balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bio Rad Laboratories are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Short Term Debt
Most indicators from Bio Rad's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. At this time, Bio Rad's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 28th of May 2024, Enterprise Value is likely to grow to about 1 B, while Selling General Administrative is likely to drop about 481.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.6B | 1.6B | 1.4B | 769.3M | Total Revenue | 2.9B | 2.8B | 2.7B | 1.4B |
Bio Rad fundamental ratios Correlations
Click cells to compare fundamentals
Bio Rad Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Rad fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.0B | 13.0B | 17.8B | 13.5B | 12.3B | 12.9B | |
Short Long Term Debt Total | 439.8M | 14.1M | 11.0M | 1.2B | 1.4B | 1.5B | |
Other Current Liab | 158.5M | 224.9M | 210.7M | 186.2M | (35.4B) | (33.6B) | |
Total Current Liabilities | 905.5M | 631.5M | 680.9M | 568.7M | 522.8M | 338.4M | |
Total Stockholder Equity | 5.8B | 9.9B | 13.7B | 9.6B | 8.7B | 9.2B | |
Property Plant And Equipment Net | 701.2M | 693.5M | 695.8M | 679.6M | 723.7M | 759.9M | |
Net Debt | (220.9M) | (648.1M) | (459.8M) | 764.0M | 1.0B | 1.1B | |
Retained Earnings | 5.5B | 9.3B | 13.5B | 9.9B | 9.3B | 9.7B | |
Cash | 660.7M | 662.2M | 470.8M | 434.2M | 404.0M | 257.1M | |
Non Current Assets Total | 5.8B | 10.8B | 15.8B | 10.3B | 9.3B | 9.7B | |
Non Currrent Assets Other | (997.7B) | (2.1T) | (3.1T) | (1.8T) | (1.5T) | (1.4T) | |
Cash And Short Term Investments | 1.1B | 996.7M | 875.5M | 1.8B | 1.6B | 1.7B | |
Net Receivables | 392.7M | 419.4M | 423.5M | 494.6M | 500.9M | 272.8M | |
Common Stock Shares Outstanding | 30.2M | 30.2M | 30.2M | 29.8M | 29.2M | 29.1M | |
Liabilities And Stockholders Equity | 8.0B | 13.0B | 17.8B | 13.5B | 12.3B | 12.9B | |
Non Current Liabilities Total | 1.3B | 2.5B | 3.4B | 3.3B | 3.0B | 3.2B | |
Inventory | 554.0M | 622.3M | 572.2M | 719.3M | 780.5M | 819.5M | |
Other Current Assets | 113.3M | 101.5M | 117.8M | 147.8M | 154.0M | 91.6M | |
Other Stockholder Equity | 371.6M | 329.5M | 335.4M | 183.9M | (183.5M) | (174.3M) | |
Total Liab | 2.3B | 3.1B | 4.1B | 3.9B | 3.6B | 3.7B | |
Property Plant And Equipment Gross | 701.2M | 1.5B | 1.5B | 1.5B | 1.8B | 1.9B | |
Total Current Assets | 2.2B | 2.1B | 2.0B | 3.2B | 3.0B | 3.2B | |
Accumulated Other Comprehensive Income | (87.3M) | 282.5M | (175.6M) | (466.8M) | (336.0M) | (319.2M) | |
Short Term Debt | 426.2M | 1.8M | 489K | 465K | 41.4M | 30.8M | |
Accounts Payable | 287.1M | 362.3M | 418.9M | 329.8M | 142.8M | 138.4M | |
Intangible Assets | 145.5M | 199.5M | 253.9M | 332.1M | 320.5M | 188.7M | |
Other Assets | 40.3M | 13K | 82K | 94.6M | 85.1M | 71.4M | |
Long Term Debt | 13.6M | 12.3M | 10.5M | 1.2B | 1.2B | 1.3B | |
Good Will | 264.1M | 291.9M | 347.3M | 406.5M | 413.6M | 339.1M | |
Treasury Stock | (38.4M) | (99.9M) | (106.3M) | (263.6M) | (237.2M) | (225.4M) | |
Property Plant Equipment | 499.3M | 491.4M | 695.8M | 498.6M | 573.4M | 371.9M | |
Current Deferred Revenue | 33.7M | 42.5M | 50.9M | 52.2M | 35.8B | 37.5B | |
Other Liab | 1.2B | 2.4B | 3.4B | 2.0B | 2.3B | 2.4B | |
Short Term Investments | 459.5M | 334.5M | 404.7M | 1.4B | 1.2B | 1.3B | |
Net Tangible Assets | 5.8B | 9.9B | 13.1B | 9.2B | 10.6B | 11.1B | |
Retained Earnings Total Equity | 5.5B | 9.3B | 13.5B | 9.9B | 11.4B | 12.0B | |
Capital Surpluse | 410.0M | 429.4M | 441.7M | 447.5M | 514.6M | 366.5M | |
Deferred Long Term Liab | 997.8M | 2.1B | 3.1B | 1.8B | 2.0B | 2.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Bio Stock analysis
When running Bio Rad's price analysis, check to measure Bio Rad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Rad is operating at the current time. Most of Bio Rad's value examination focuses on studying past and present price action to predict the probability of Bio Rad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Rad's price. Additionally, you may evaluate how the addition of Bio Rad to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Bio Rad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.797 | Earnings Share (10.68) | Revenue Per Share 90.024 | Quarterly Revenue Growth (0.1) | Return On Assets 0.0169 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.